American Diabetes Association

Skip to Main Content

Table 4—

LIPC C → T variance and HL activity (units/l) after 30 weeks of treatment

Genotype	n	Placebo	Atorvastatin
Genotype	n	Placebo				10 mg	80 mg
CC genotype	109
Baseline		437 ± 124	448 ± 140	447 ± 129
30 weeks		441 ± 139	402 ± 156^*	348 ± 98^*
CT genotype	74
Baseline		352 ± 144	357 ± 121	366 ± 157
30 weeks		349 ± 137	319 ± 128^*	280 ± 128^*
TT genotype	15
Baseline		224 ± 76	306 ± 104	257 ± 76
30 weeks		236 ± 137	273 ± 34	209 ± 45

Genotype	n	Placebo	Atorvastatin
Genotype	n	Placebo				10 mg	80 mg
CC genotype	109
Baseline		437 ± 124	448 ± 140	447 ± 129
30 weeks		441 ± 139	402 ± 156^*	348 ± 98^*
CT genotype	74
Baseline		352 ± 144	357 ± 121	366 ± 157
30 weeks		349 ± 137	319 ± 128^*	280 ± 128^*
TT genotype	15
Baseline		224 ± 76	306 ± 104	257 ± 76
30 weeks		236 ± 137	273 ± 34	209 ± 45

Data are means ± SD.

*

P < 0.001, significantly different from baseline in each treatment group.